Wikipedia -WSS

Wikipedia

author：explore 2025-10-04 08:50:45 Page View：19713

Roche HQ — SEBASTIEN BOZON/AFP via Getty Images

The multibillion-dollar hunt for what many drugmakers hope will be the next big immunotherapy target has had no shortage of twists and tea-leaf-reading. In the wee hours of Wednesday morning, it got another.

Roche confirmed it accidentally released interim data from a closely watched clinical trial testing whether blocking that target — a protein on T cells known as TIGIT — can enable non-small lung cancer patients to live longer than standard immunotherapy alone.

The announcement release came hours after Evercore analyst Umer Raffat emailed investors that he had found a presentation on a Roche media portal, presumably uploaded by accident.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Covid isolation guidance eased by the CDC
Next article： Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

explore

Novavax promises a turnaround & Lilly roils the obesity market

SammyKimballforSTATCanNovavaxfinallygetitright?What’sa“triple-G”drug?AndisNovoNordisklosingground?We

ALS groups 'won't be played again' by the FDA, drug sponsors

MattScozzariholdshisgirlfriendSabrinaParker'shandduringafriendshipceremonyinJacksonville,N.C.,inNove

Supreme Court strikes down use of affirmative action

ActivistsdemonstratedastheSupremeCourtheardoralargumentsonapairofaffirmativeactioncasesinOctober2022

FDA approves Recor Medical high blood pressure device

ReCorMedical,astartupownedbyJapanesecompanyOtsukaMedicalDevices,andMedtronichaverunstudiesthatshowed

Wikipedia

focus

explore

FDA approves Recor Medical high blood pressure device